SecBot SecBot
COURT-RULING ·Filed Jul 13, 2026

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD
BULLISH
Impact 6/10
Horizonmonths Processed4mo ago CourtCourt Ruling · govinfo.gov
Court ruling (appellate)
Actionable Insight ▲ Bullish

The reversal removes a significant legal barrier for Teva's breach-of-contract claim against Lilly. Monitor for discovery developments and potential settlement discussions; a favorable outcome could unlock damages from lost generic Forteo sales during the exclusivity period. The case now proceeds to merits discovery.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.82
T+0 close · Jul 14, 2026 · via day close
Latest settled
+23.13%
T+60 · $39.18
Vs SPY
+19.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 14 $31.82entry
  2. T+1 · 4mo ago −0.82%α −1.21% · $31.56
  3. T+5 · 4mo ago −1.48%α −1.00% · $31.35
  4. T+20 · 3mo ago +14.64%α +12.15% · $36.48
  5. T+60 · 6w ago +23.13%α +19.50% · $39.18
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The Seventh Circuit reversed the district court's dismissal of Teva's breach-of-contract claim against Eli Lilly, holding that Teva plausibly alleged Lilly violated a 2018 settlement agreement by seeking additional regulatory exclusivity that blocked Teva's generic Forteo entry. The case is remanded for further proceedings, reviving Teva's claim that Lilly's covenants not to obstruct generic competition survived the expiration of the underlying patents.

Court Ruling Details

Ruling Date
Jul 13, 2026
Court
United States Court of Appeals for the Seventh Circuit
Court Level
Appellate
Judge
Hamilton
Case Type
contract
Ruling Type
final judgment
Outcome
WIN: ruling favors this company
Precedent Risk
LOW

Key Facts

  • Seventh Circuit reversed dismissal of Teva's breach-of-contract claim against Eli Lilly
  • Teva alleged Lilly violated a 2018 settlement agreement by obtaining 3 years of additional regulatory exclusivity (Nov 2020–Nov 2023) that blocked Teva's generic Forteo entry
  • District court had ruled the settlement agreement expired when Forteo patents expired (Aug 19, 2019); Seventh Circuit found the agreement's duration is a factual question not resolvable on the pleadings
  • Teva's covenant not to sue and other provisions plausibly survived patent expiration, supporting that Lilly's non-obstruction covenant also remained in effect
  • Case remanded for further proceedings on the merits

Financial Impact

Potential damages from lost generic Forteo market access during Nov 2020–Nov 2023 exclusivity period; no dollar amount stated in the opinion

revenuemarket_sharelegal_exposure

Risk Factors

  • Teva must still prove breach, causation, and damages on remand
  • Lilly may seek interlocutory appeal or certiorari
  • Litigation could extend for years with uncertain outcome

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-25219da5fd-TEVA

Track record

61 reports on TEVA

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 14 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens in 8h 16m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Jul 14, 2026